GlassScriptPhysician profile
Phoebe Marcella Knight
NPI 1497418180
$6,362.08
in general payments reported to CMS, 2019-2025
27 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.93 · 2022: $1,645 · 2023: $1,876 · 2024: $1,271 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,226 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.75 |
| Education | $399.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $771.23 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Janssen Biotech, INC. | $756.38 | 2022-2025 | Tremfya |
| Abbvie INC. | $728.95 | 2022-2025 | |
| Incyte Corporation | $511.95 | 2023-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $498.06 | 2022-2024 | Sotyktu |
| Leo Pharma INC. | $382.52 | 2021-2025 | Adbry |
| Dermavant Sciences, INC. | $336.48 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $293.34 | 2022-2025 | |
| Galderma Laboratories, L.P. | $286.22 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Genzyme Corporation | $268.95 | 2021-2025 | |
| Lilly USA, LLC | $260.61 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Mayne Pharma Commercial LLC | $215.67 | 2022-2025 | |
| Pfizer INC. | $156.65 | 2021-2025 | |
| Ucb, INC. | $127.17 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $125.65 | 2023-2025 | Dupixent, Libtayo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $115.26 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $115.26 | 2022-2024 | Arazlo, Jublia, Cabtreo |
| Almirall LLC | $82.60 | 2022-2023 | Seysara |
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Arcutis Biotherapeutics, INC. | $64.68 | 2024-2025 | Zoryve |
| Biofrontera INC. | $37.07 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Botanix Sb INC | $35.09 | 2025 | Sofdra |
| Journey Medical Corporation | $28.53 | 2022 | |
| Fresenius Kabi USA, LLC | $26.12 | 2023 | |
| Genentech USA, INC. | $20.85 | 2022 | |
| Amgen INC. | $18.76 | 2023 | Otezla |
| Lnhc, INC | $18.04 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phoebe Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.